EUCTR2010-022915-21-FI进行中（未招募）不适用
Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTEST
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent (IC) obtained.
- •2.Male or female patients with idiopathic PD according to the United Kingdom brain bank criteria with end-of-dose motor fluctuations
- •3. Hoehn and Yahr stage 2-4 performed during the ON” state.
- •4. Duration of response between 1.5 and 4 hours (based on medical history) to the patient’s first morning dose of levodopa/dopa decarboxylase inhibitor (DDCI) with or without entacapone.
- •5. Treatment with 3-8 daily doses of levodopa/DDCI with or without entacapone with a total daily levodopa dose in the range of 300-1200 mg. One evening dose of controlled-release formulation of levodopa/DDCI is allowed provided that it is included in the total of 3-8 daily doses of levodopa/DDCI mentioned above.
- •6. Unchanged levodopa/DDCI with or without entacapone and other antiparkinsonian medication (dopamine agonists, monoamine oxidase [MAO] B inhibitor, amantadine and/or anticholinergics with approved doses), if any, for at least 6 weeks prior to the screening visit.
- •7. Age of 30 years or above.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Secondary or atypical parkinsonism.
- •2. Use of tolcapone within 6 weeks prior to the first treatment period.
- •3. Previous tolerability problems with entacapone or tolcapone.
- •4. Concomitant treatment with apomorphine, MAO-A inhibitors or non-selective MAO inhibitors.
- •5. Concomitant treatment with drugs having antidopaminergic action including alpha-methyldopa, reserpine and antipsychotic drugs (also D2 receptor blocking antiemetics except domperidone). As an exception, an evening dose of an atypical antipsychotic is allowed.
- •6. Use of any iron preparations.
- •7. Intensity of dyskinesias which would, in the opinion of the investigator, interfere with the interpretation of motor part (part III) of the Unified Parkinson’s Disease Rating Scale (UPDRS III) scoring during the levodopa challenge test.
- •8. Currently active hallucinations.
- •9. Severe orthostatic hypotension as judged by the investigator.
- •10. Mini-Mental State Examination (MMSE) score < 26
- •11. History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.
- •12. Past or current treatment with deep brain stimulation (DBS) or other surgical treatment for PD.
- •13. Treatment with levodopa or dopamine agonist infusion or injection
- •14. Active malignancy, narrow-angle glaucoma or pheochromocytoma.
- •15. Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
- •16. Alanine aminotransferase or aspartate aminotransferase > upper limit of normal at screening.
- •17. Any other abnormal value of laboratory, vital signs or electrocardiogram (ECG) which would in the opinion of the investigator interfere with the interpretation of the study results or cause health risk for the subject if he/she takes part into the study.
- •18. Female patients of childbearing potential (i.e. menstruating or less than 2 years postmenopausal) if they are not using proper contraception (hormonal contraception, intrauterine device [IUD] or surgical sterilisation, spermicidal foam in conjunction with condom on male partner).
- •19. Patients with pre-planned elective surgery.
- •20. Known hypersensitivity to active substances or to any of the excipients of the study drugs.
- •21. Participation in a drug study within 60 days prior to entry to this study.
- •22. Any other condition that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part into the study.
研究者
相似试验
进行中（未招募）
不适用
Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multicentre, single dose study in patients with Parkinson’s disease and wearing-off symptoms - PARTESTParkinson's diseaseMedDRA version: 12.1Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2010-022915-21-SEOrion Corporation27
招募中
3 期
Dexmedetomidine as an adjuvant to levobupivacaine andlidocaine in ultrasound-guided superficial cervical block forcarotid endarterectomy: a prospective, randomised, double-blinded studyACTRN12622000942752niversity hospital centre Sestre Milosrdnice60
招募中
不适用
Assessment of possible effects of manual therapy on the nervous systemeuromuscular ManifestationsC10.668RBR-5syg5gkniversidade Federal do ABC
已完成
不适用
An investigation into the effect of neuromuscular electrical stimulation (NMES) and pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD)ISRCTN46428072Record Provided by the NHSTCT Register - 2007 Update - Department of Health40
尚未招募
Unknown
Comparison of the duration of sensory anaesthesia in patients undergoing lower limb orthopaedic surgery under spinal anaesthesia with & without intravenous dexmedetomidine.CTRI/2023/06/054571Maulana Azad Medical College